To examine the impact of anxiety disorders comorbid to bipolar disorder (BD) in a large, nationally representative sample, to describe the sociodemographic and clinical profiles of Canadians living with BD and with or without comorbid anxiety disorders, to identify the characteristics uniquely associated with comorbid anxiety, and to examine treatment patterns.
Method:
We analyzed data from the Canadian Community Health Survey: Mental Health and Well-Being, conducted among 38 492 Canadians. People meeting the criteria for BD (n = 808) were compared based on the presence or absence of an assessed anxiety disorder (that is, social phobia, panic disorder, and agoraphobia).
Results:
People with BD and a comorbid anxiety disorder fare worse in terms of BD relapses, suicidality, and sleep disturbance, and are more likely to be taking psychiatric medication. They have more impairment in their work and social functioning and rate their health and life satisfaction lower. Despite the greater severity, they are not receiving additional psychological treatment, they feel they are not receiving the treatment they need, and they report more barriers to treatment.
Conclusions:
This study confirms the critical impact of comorbid anxiety on the course of BD in a large, nationally representative sample and reveals that the psychological treatment needs of this population are not being met. Clinical and research implications are discussed.
American Psychiatric Association (APA)Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington (DC): APA; 2001.
2.
SchafferACairneyJCheungACommunity survey of bipolar disorder in Canada: Lifetime prevalence and illness characteristics. Can J Psychiatry. 2006;51(1):9–16.
3.
BenazziF.Inter-episode mood lability in mood disorders: Residual symptom or natural course of illness?Psychiatry Clin Neurosci. 2004;58(5):480–486.
4.
PaykelESAbbottRMorrissRSub-syndromal and syndromal symptoms in the longitudinal course of bipolar disorder. Br J Psychiatry. 2006;189:118–123.
5.
SubletteEMCarballoJJMorenoCSubstance use disorders and suicide attempts in bipolar subtypes. J Psychiatr Res. 2009;43(3):230–238.
6.
JuddLLAkiskalHS. The prevalence and disability of bipolar spectrum disorders in the US population: Re–analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003;73(1–2):123–131.
7.
Das GuptaRGuestJF. Annual cost of bipolar disorder to UK society. Br J Psychiatry. 2002;180:227–233.
8.
StenslandMDJacobsonJGNyhuisA.Service utilization and associated direct costs for bipolar disorder in 2004: An analysis in managed care. J Affect Disord. 2007;101(1–3):187–193.
9.
BrissosSDiasVVCaritaAIQuality of life in bipolar type I disorder and schizophrenia in remission: Clinical and neurocognitive correlates. Psychiatry Res. 2008;160(1):55–62.
10.
LeeSNgKLTsangA.A community survey of the twelve-month prevalence and correlates of bipolar spectrum disorder in Hong Kong. J Affect Disord. 2009;117(1–2):79–86.
11.
MerikangasKRAkiskalHSAngstJLifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007;64(5):543–552.
12.
SchafferACairneyJVeldhuizenSA population-based analysis of distinguishers of bipolar disorder from major depressive disorder. J Affect Disord. 2010;125(1–3):103–110.
13.
FreemanMPFreemanSAMcElroySL. The comorbidity of bipolar and anxiety disorders: Prevalence, psychobiology, and treatment issues. J Affect Disord. 2002;68(1):1–23.
14.
DilsaverSCBenazziFAkiskalKKDifferential patterns of lifetime multiple anxiety disorder comorbidity between Latino adults with bipolar I and major depressive disorders. Bull Menninger Clin. 2008;72(2):130–148.
15.
WozniakJBiedermanJMonuteauxMCParsing the comorbidity between bipolar disorder and anxiety disorders: A familial risk analysis. J Child Adolesc Psychopharmacol. 2002;12(2):101–111.
16.
El-MallakhRSHollifieldM.Comorbid anxiety in bipolar disorder alters treatment and prognosis. Psychiatr Q. 2008;79(2):139–150.
17.
CoryellWSolomonDAFiedorowiczJGAnxiety and outcome in bipolar disorder. Am J Psychiatry. 2009;166(11):1238–1243.
18.
OttoMWSimonNMWisniewskiSRProspective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry. 2006;189:20–25.
19.
FeskeUFrankEMallingerAGAnxiety as a correlate of response to the acute treatment of bipolar I disorder. Am J Psychiatry. 2000;157(6):956–962.
20.
SimonNMZaltaAKOttoMWThe association of comorbid anxiety disorders with suicide attempts and suicidal ideation in outpatients with bipolar disorder. J Psychiatr Res. 2007;41(3–4):255–264.
21.
AlbertURossoGMainaGImpact of anxiety disorder comorbidity on quality of life in euthymic bipolar disorder patients: Differences between bipolar I and II subtypes. J Affect Disord. 2008;105(1–3):297–303.
22.
FracalanzaKAMcCabeRETaylorVHBipolar disorder comorbidity in anxiety disorders: Relationship to demographic profile, symptom severity, and functional impairment. Eur J Psychiatry. 2011;25(4):223–233.
23.
KesslerRCMerikangasKRWangPS. Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol. 2007;3:137–158.
24.
ProvencherMDHawkeLDThienotE.Psychotherapies for comorbid anxiety in bipolar spectrum disorders. J Affect Disord. 2011;133(3):371–380.
25.
ProvencherMDGuimondA–JHawkeLD. Comorbid anxiety in bipolar spectrum disorders: A neglected research and treatment issue?J Affect Disord. 2012;137(1–3):161–164.
26.
GravelRBélandY.The Canadian Community Health Survey: Mental health and well-being. Can J Psychiatry. 2005;50(10):573–579.
27.
KesslerRCÜstünTB. The World Mental Health (WMH) survey initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res. 2004;13(2):93–121.
28.
PlanteDTWinkelmanJW. Sleep disturbance in bipolar disorder: Therapeutic implications. Am J Psychiatry. 2008;165(7):830–843.
29.
SchafferAMcIntoshDGoldsteinBIThe CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012;24(1):6–22.
30.
SassonYChopraMHarrariEBipolar comorbidity: From diagnostic dilemmas to therapeutic challenge. Int J Neuropsychopharmacol. 2003;6(2):139–144.
31.
ChouinardG.Issues in the clinical use of benzodiazepines: Potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65(5):7–21.
32.
Kauer–Sant'AnnaMKapczinskiFVietaE.Epidemiology and management of anxiety in patients with bipolar disorder. CNS Drugs. 2009;23(11):953–964.
33.
OttoMWReilly-HarringtonN.Cognitive-behavioral therapy for the management of bipolar disorder. In: HofmannSGTompsonMC, editors. Treating chronic and severe mental disorders: A handbook of empirically supported interventions. New York (NY): Guilford Press; 2002. p. 116–130.
34.
RizviSZaretskyAE. Psychotherapy through the phases of bipolar disorder: Evidence for general efficacy and differential effects. J Clin Psychol. 2007;63(5):491–506.
35.
American Psychiatric Association (APA)DSM-5 development [Internet]. Arlington (VA): APA; 2012 [cited 2012 Jun 19]. Available from: http://www.dsm5.org.
36.
WittchenHU. Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): A critical review. J Psychiatr Res. 1994;28(1):57–84.
